Minimum inhibitory concentrations of cephalosporin compounds and their active metabolites for selected mastitis pathogens

American Journal of Veterinary Research

Volumn 74, Issue 5, 2013, Pages 683-690

  Cortinhas, Cristina S ^a   Oliveira, Leane ^b   Hulland, Carol A ^b   Santos, Marcos V ^a   Ruegg, Pamela L ^b  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFAPIRIN; CEFTIOFUR; DEACETYLCEFAPIRIN; DESFUROYLCEFTIOFUR; DRUG METABOLITE; UNCLASSIFIED DRUG;

AGAR DILUTION; ANTIBIOTIC SENSITIVITY; ARTICLE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; COW; CROSS RESISTANCE; ESCHERICHIA COLI; GROWTH INHIBITION; KAPLAN MEIER METHOD; MASTITIS; METABOLITE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PATHOGENESIS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS DYSGALACTIAE; STREPTOCOCCUS UBERIS; SURVIVAL;

ESCHERICHIA COLI; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS DYSGALACTIAE; STREPTOCOCCUS UBERIS;

EID: 84877067252     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.74.5.683     Document Type: Article

References (27)

1. Bradley AJ. Bovine mastitis: an evolving disease. Vet J 2002;164:116-128.
2. Sawant AA, Sordillo LM, Jayarao BM. A survey on antibiotic usage in dairy herds in Pennsylvania. J Dairy Sci 2005;88:2991-2999.
3. Pol M, Ruegg PL. Relationship between antimicrobial drug usage and antimicrobial susceptibility of gram-positive mastitis pathogens. J Dairy Sci 2007;90:262-273.
4. Hornish RE, Kotarski SF. Cephalosporins in veterinary medicine-ceftiofur use in food animals. Curr Top Med Chem 2002;2:717-731.
5. Salmon SA, Watts JL, Yancey RJ. In vitro activity of ceftiofur and its primary metabolite, desfuroylceftiofur, against organisms of veterinary importance. J Vet Diagn Invest 1996;8:332-336.
6. Pinzón-Sánchez C, Ruegg PL. Risk factors associated with short-term post-treatment outcomes of clinical mastitis. J Dairy Sci 2011;94:3397-3410.
7. Cabana BE, Van Harken DR, Hottendorf GH. Comparative pharmacokinetics and metabolism of cephapirin in laboratory animals and humans. Antimicrob Agents Chemother 1976;10:307-317.
8. Jones RN, Packer RR. Cefotaxime, cephalothin, and cephapirin: antimicrobial activity and synergy studies of cephalosporins with significant in vivo desacetyl metabolite concentrations. Diagn Microbiol Infect Dis 1984;2:65-68.
9. Moats WA, Anderson KL, Rushing JE, et al. Conversion of cephapirin to deacetylcephapirin in milk and tissues of treated animals. J Agric Food Chem 2000;48:498-502.
10. Stockler RM, Morin DE, Lantz RK, et al. Effect of milk fraction on concentrations of cephapirin and desacetylcephapirin in bovine milk after intramammary infusion of cephapirin sodium. J Vet Pharmacol Ther 2009;32:345-352.
11. Stockler RM, Morin DE, Lantz RK, et al. Effect of milking frequency and dosing interval on the pharmacokinetics of cephapirin after intramammary infusion in lactating dairy cows. J Dairy Sci 2009;92:4262-4275.
12. Constable PD, Morin DE. Treatment of clinical mastitis: using antimicrobial susceptibility profiles for treatment decisions. Vet Clin North Am Food Anim Pract 2003;19:139-155.
13. Erskine RJ, Bartlett PC, Vanlente JL, et al. Efficacy of systemic ceftiofur as a therapy for severe clinical mastitis in dairy cattle. J Dairy Sci 2002;85:2571-2575.
14. Hoe FGH, Ruegg PL. Relationship between antimicrobial susceptibility of clinical mastitis pathogens and treatment outcome in cows. J Am Vet Med Assoc 2005;227:1461-1468.
15. Apparao D, Oliveira L, Ruegg PL. Relationship between results of in vitro susceptibility tests and outcomes following treatment with pirlimycin hydrochloride in cows with subclinical mastitis associated with gram-positive pathogens. J Am Vet Med Assoc 2009;234:1437-1446.
16. Apparao MD, Ruegg PL, Lago A, et al. Relationship between in vitro susceptibility test results and treatment outcomes for gram- positive mastitis pathogens following treatment with cephapirin sodium. J Dairy Sci 2009;92:2589-2597.
17. Pantoja JCF, Hulland C, Ruegg PL. Dynamics of somatic cell counts and intramammary infections across subsequent lactations. Prev Vet Med 2009;90:43-54.
18. Lago A, Godden SM, Bey R, et al. The selective treatment of clinical mastitis based on on-farm culture results: II. Effects on lactation performance including, clinical mastitis recurrence, somatic cell count, milk production and cow survival. J Dairy Sci 2011;94:4457-4467.
19. Olivera L, Langoni H, Hulland C, et al. Minimum inhibitory concentration of Staphylococcus aureus recovered from clinical and subclinical cases of bovine mastitis. J Dairy Sci 2012;95:1913-1920.
20. Richert RM, Cicconi KM, Gamroth MJ, et al. The role of the veterinarian on organic and conventional dairy farms. J Am Vet Med Assoc 2013;in press.
21. National Mastitis Council. Laboratory handbook on bovine mastitis. Madison, Wis: National Mastitis Council, 1999.
22. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals. Approved standard. 3rd ed. CLSI document M31-A3. Wayne, Pa: Clinical and Laboratory Standards Institute, 2007.
23. SAS user's guide: statistics. Version 9.1 edition. Cary, NC: SAS Institute Inc, 2008.
24. Guérin-Faublée V, Carret G, Houffschmitt P. In vitro activity of 10 antimicrobial agents against bacteria isolated from cows with clinical mastitis. Vet Rec 2003;152:466-471.
25. Smith GW, Gehring R, Riviere JE, et al. Elimination kinetics of ceftiofur hydrochloride after intramammary administration in lactating dairy cows. J Am Vet Med Assoc 2004;224:1827-1830.
26. Makovec JA, Ruegg PL. Results of milk samples submitted for microbiological examination in Wisconsin from 1994 to 2001. J Dairy Sci 2003;86:3466-3472.
27. Pyörälä S. Treatment of mastitis during lactation. Ir Vet J 2009;62:S40-S44.